CJC-1295 vs Egrifta (Tesamorelin): Cost and Access Head-to-Head
HealthRX.com
No verified price exists for either product
At a glance
- FDA status / tesamorelin approved November 10, 2010 (BLA 022505); no approved CJC-1295 product where FDA searched [4][3]
- Labeled use / excess abdominal fat in HIV-infected adults with lipodystrophy; not weight loss [1]
- Label dose / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; not substitutable [1][2]
- CJC-1295 compounding / in no category of FDA's pharmacy or outsourcing-facility lists [5][6]
- Human evidence / tesamorelin: two phase 3 trials pooling 806 patients [7]; CJC-1295: three published studies, all in healthy volunteers [3]
- Price / no verified price or coverage information available
What each product is
Tesamorelin is the approved drug. FDA approved Egrifta (tesamorelin acetate) on November 10, 2010 under BLA 022505 [4]. The current labels are Egrifta SV (a 2 mg vial) and Egrifta WR (an 11.6 mg vial), both dated July 29, 2026. Both are once-daily subcutaneous injections with one labeled use: reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1][2]. The label says it is not indicated for weight loss because its effect on weight is neutral [1].
CJC-1295 is not approved. FDA found no approved product containing any form of CJC-1295 in the twelve countries it searched, and none authorized by the European Medicines Agency [3]. FDA identified only three published human studies, all of the DAC form and all in healthy volunteers. A phase 2 trial in HIV lipodystrophy (192 enrolled) was withdrawn in 2006 after a participant died. The data were never published, so a causal link is neither shown nor excluded [3].
Price, coverage and the regulatory split
No verified price, copay or payer rule is available for either product, so the difference that can be documented is regulatory. CJC-1295 appears in no category of FDA's lists for state-licensed pharmacies and physicians or for outsourcing facilities [5][6]. It sits in the nominated-but-withdrawn table on FDA's significant-safety-risk page, where FDA's stated concerns remain posted, including serious adverse events such as increased heart rate and a systemic vasodilatory reaction [8]. Tesamorelin is absent from that page and from both lists, so FDA has made no category-based statement about compounding it [8][5][6]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [9].
What people on Reddit report
Accounts from people who have run both peptides side by side and compared what each costs and how each is stored.
In my research and validated by dexa scans they are effectively the same. But, cjc/ipa is far more affordable to research over a 12 week period.Read the source discussion
They arent different tools. They literally do the same thing. They both boost GH which helps burn visceral fat. One just happens to be FDA approved and way more expensive.Read the source discussion
Questions worth asking
Dosing, preparation and monitoring
The labels give Egrifta SV as 1.4 mg once daily and Egrifta WR as 1.28 mg once daily, both injected subcutaneously into the abdomen, and state that the two are not substitutable [1][2]. The Egrifta SV label specifies Sterile Water for Injection for reconstitution, immediate administration after mixing, and disposal of unused solution. The Egrifta WR label specifies Bacteriostatic Water for Injection, with one reconstituted vial supplying seven daily doses [1][2]. The labels say to monitor IGF-1 and to evaluate glucose before and during therapy [1].
There is no approved CJC-1295 label, so no label dose or monitoring schedule exists for it. In Teichman 2006, single doses of the DAC form in healthy adults gave an estimated half-life of 5.8 to 8.1 days, and no serious adverse reactions were reported [10]. That study measured pharmacokinetics and short-term GH and IGF-I responses, not health outcomes, and its doses are not recommended doses. No human study of any CJC-1295 form has shown a health benefit [3][10].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is CJC-1295 cheaper than Egrifta?
Does insurance cover Egrifta or CJC-1295?
Can CJC-1295 be compounded?
What is the approved dose of Egrifta?
Is tesamorelin approved for weight loss?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is Tesamorelin or CJC-1295 better?
No ranking is established. Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while no approved CJC-1295 product was found in the countries FDA searched. CJC-1295's three published human studies all used healthy volunteers, and no human study of any CJC-1295 form has shown a health benefit.
What is the average cost of Tesamorelin peptide?
No verified average cost exists, so no figure can be given for tesamorelin or CJC-1295. No verified price, copay or payer rule is available for either product. Egrifta is sold as Egrifta SV (a 2 mg vial) and Egrifta WR (an 11.6 mg vial), but the vial sizes do not establish what either costs.
Is Tesamorelin worth the cost?
Whether it is worth the cost cannot be judged from the available data, because no verified price or coverage information exists for either product. What is documented is that Egrifta is FDA-approved for one labeled use, reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and the label says it is not indicated for weight loss.
References
Show all 13 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- U.S. Food and Drug Administration.
- Drugs@FDA: FDA-Approved Drugs.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- U.S. Food and Drug Administration.
- Reddit participants. Peptides Tesamorelin vs CJC-1295 (No DAC) Two GHRH Analogs (r/NTNPerformance). Accessed 2026-11-10.
- Reddit participants. Tesamorelin vs CJC-1295 (No DAC): why they're not interchangeable (r/NTNPerformance). Accessed 2026-11-10.